PEA-15 (phospho Ser104) Polyclonal Antibody

Rabbit Anti-PEA-15 (phospho Ser104) Polyclonal Antibody

Product Specifications

Background

PEA15 (phosphoprotein enriched in astrocytes 15) encodes a death effector domain-containing protein that functions as a negative regulator of apoptosis. The encoded protein is an endogenous substrate for protein kinase C. This protein is also overexpressed in type 2 diabetes mellitus, where it may contribute to insulin resistance in glucose uptake. Alternative splicing results in multiple transcript variants.

CAS Number

9007-83-4

Product Name Alternative

PEA15; Astrocytic phosphoprotein PEA-15; 15 kDa phosphoprotein enriched in astrocytes; Phosphoprotein enriched in diabetes; PED

Gene ID

8682

Accession Number

Q15121

Reactivity

Human, Mouse, Rat, Monkey

Immunogen

Synthesized peptide derived from human PEA-15 around the phosphorylation site of S104

Clonality

Polyclonal

Tag

Astrocytic phosphoprotein PEA-15

Applications

WB, IHC, IF, ELISA

Purification Method

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration

1 mg/ml

Molecular Weight

19kD

Precautions

The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Shipping Conditions

Gel pack with blue ice.

Storage Conditions

Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Notes

Phospho-PEA-15 (S104) Polyclonal Antibody detects endogenous levels of PEA-15 protein only when phosphorylated at S104.

Observed Molecular Weight

Formulation

Liquid solution

Buffer pH

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Applications Notes

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:20000; IF 1:50-200